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BACKGROUND: Opioid use disorder (OUD) is a chronic, debilitating and costly disorder with 
an unprecedented increase in prevalence in many countries. Maintenance opioid agonist 
therapy (OAT) with oral methadone or sublingual buprenorphine is the first-line, empirically-
supported treatment. However, many patients do not stop using illicit or non-prescribed drugs 
while enrolled in OAT. To address this, we developed a personalised psychosocial 
intervention (PSI) as an adjunct to continued OAT implemented with a toolkit of behaviour 
change techniques. The aim was to estimate if the PSI was effective and cost-effective.  
 
METHODS: This was a pragmatic, open-label, randomised controlled trial at a specialist NHS 
community addictions clinic in England. We recruited adults enrolled in OAT for a median of 
26 weeks (IQR 10-88), voluntarily seeking continued OAT, who were treatment-resistant 
(defined as using illicit or non-prescribed opioids and/or cocaine on one or more days in the 
past 28 days at study screening and verified by positive urine drug screen).  
 
Participants were allocated (1:1) by a web-accessed randomisation sequence (stratified by 
OAT medication, current cocaine use, and current injecting) to receive continued standard 
OAT (treatment-as-usual, TAU) or standard OAT and personalised PSI. Outcome data were 
collected by independent research assistants. The primary outcome was treatment response 
at 18 weeks, defined as abstinence from illicit and non-prescribed opioids and cocaine in the 
past 28 days recorded by the Treatment Outcomes Profile and negative urine drug screen.  
 
Taking a societal cost perspective, an evaluation of cost-effectiveness was done by taking a 
wide range of values of willingness-to-pay (WTP) for a unit improvement in the probability of 
treatment response, and EQ-5D-3L derived quality adjusted life years (QALYs). The planned 
analysis was intention-to-treat (ITT), including all those who were randomly allocated. This 
trial is registered with the ISRCTN registry, number ISRCTN69313751. 
 
FINDINGS: Between June 7, 2013 and December 21, 2015, we randomly allocated 136 
participants (50%) to the PSI group and 137 participants (50%) to the TAU group. The trial 
database was locked for analysis on April 19, 2017. In error, we re-randomised three 
participants. These cases were excluded from all analysis. Due to this error, the analysis is 
classified as a modified ITT (mITT). All other randomised participants were included.  
 
In the mITT analysis, treatment response was greater in the PSI group (22 [16·3%] of 135) 
compared to the TAU group (9 [6·7%] of 135; adjusted log odds 1·20, 95% CI 0·01 to 2·37, p-
value=0·048). The PSI had a higher probability of being cost-effective than TAU. There was a 
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probability range of 47% to 87% for WTP thresholds of £0 to £1,000 for a unit Improvement in 
the probability of treatment response. QALYs were higher in the PSI group than the TAU 
(mean difference 0·048, 95% CI 0·016 to 0·080, p-value=0·004), with a 60% and 67% 
probability of cost-effectiveness at the NICE willingness to pay thresholds of £20,000 and 
£30,000 per QALY, respectively.   
 
There was no statistically significant difference in the number of adverse events. One 
participant in the TAU group was hospitalised with acute sepsis and died, another was 
hospitalised with head injury. One participant in the PSI group was hospitalised with a panic 
attack. None of these severe adverse events was judged to be trial-related. 
  
INTERPRETATION: In maintenance opioid agonist therapy, an adjunctive personalised 
psychosocial intervention was effective and cost-effective at helping treatment-resistant 
patients abstain from using illicit and non-prescribed opioids and cocaine. During on-going 
opioid agonist therapy, a personalised psychosocial intervention can enable treatment to be 
effectively tailored to individual need. 
  




















RESEARCH IN CONTEXT 
 
Evidence before this study 
Including all randomised controlled trials published to November 2006, the UK National 
Institute of Health and Care Excellence (NICE; Clinical Guideline 51) on psychosocial 
interventions (PSI) for drug misuse (no amendments or additions since) endorsed only 
behavioural reinforcement ('contingency management' [CM]), behavioural couple and family 
interventions, and 12-Step-based groups for opioid use disorder (OUD). 
We conducted searches of Cochrane Library, Scopus, Psychinfo and PubMed for relevant 
systemic reviews, reports of meta-analysis, and individual trial reports of PSI adjunctive to 
maintenance opioid agonist treatment (OAT) between November 2006 to May 2018. Search 
terms included, "heroin* (OR cocaine* OR crack OR opiate* OR opioid* OR methadone OR 
buprenorphine) AND adjunctive OR psychosocial OR psychotherapy", and article types were 
clinical trials or randomised controlled trials. We identified 191 relevant studies with no study 
including non-response to OAT as an inclusion criterion. 
Added value of this study 
This is the first study, to our knowledge, examining the effectiveness of an adjunctive, 
personalised PSI for patients who are retained in ongoing OAT and are using illicit and non-
prescribed opioids and/or cocaine. The results indicated that a personalised PSI is an 
effective means of helping patients abstain from these drugs (or use them less often) and 
achieve better social functioning. The economic evaluation indicated that the additional costs 
of the PSI were more than offset by the significantly greater reductions in crime related costs 
among intervention participants compared to TAU.  
 
Implication of all the available evidence 
Appropriately trained and supervised assistant psychologists can deliver an effective and cost-
effective personalised PSI to OAT-resistant patients. This clinical population should be offered 










Opioid use disorder (OUD) is a chronic and debilitating psychiatric condition associated with a 
high global burden of disease [1] and substantial social costs (£13·9 billion in England and 
Wales in 2014) [2]. Internationally in recent years, there has been an unprecedented increase 
in the prevalence of OUD and opioid poisoning mortality [3]. 
 
The first-line intervention for OUD is maintenance opioid agonist treatment (OAT) with oral 
methadone (a full mu-opioid receptor agonist; usual dose: 60-120 mg/day) or sublingual 
buprenorphine (a partial mu-agonist [also available in a 4:1 formulation with naloxone]; usual 
dose 12-24 mg/day). In the United Kingdom (UK), patients are enrolled in community 
treatment services providing OAT, receive medical management and are assigned a clinical 
key worker (often a nurse) for general drug counselling and support [4].  
Systematic review evidence from trials of OAT for illicit OUD [5] suggests that flexible dose 
methadone maintenance is more effective than flexible dose buprenorphine maintenance at 
retaining patients (six trials with 837 participants; relative risk [RR] 0·82, 95% confidence 
interval [CI] 0·69 to 0·96), but with no statistical difference for the suppression of heroin use 
(mean difference -0·12 days, 95% CI -0·32 to 0·12). For pharmaceutical OUD [6], there is no 
statistically significant difference between methadone and buprenorphine for retention (three 
studies, 360 participants, RR 0·69, 95% CI 0·39 to 1·22) or suppression of non-prescribed 
opioid use (mean difference -1·41 days, 95% CI -3·37 to 0·55).  
There are three issues of concern about OAT in routine practice. Despite efforts to select the 
best medication and dose for each patient, many discontinue treatment [7]. Other patients are 
retained but may not take their prescription as directed or continue to use illicit or non-
prescribed pharmaceutical opioids (herein 'opioids'), or relapse to pre-treatment levels. For 
example, in an English study of 12,745 patients enrolled for 12-26 weeks, 63·5% were using 
opioids on 10 or more of the past 28 days at clinical review [8]. Cocaine use disorder 
(particularly with the base form crack) [9], and co-occurring anxiety and mood disorders are 
prevalent in the clinical OUD population and can moderate OAT engagement and response 
[10,11]. Family relationships and social networks can either support or hinder recovery [12]. 
 
Adjunctive psychosocial intervention (PSI) in the form of a stand-alone, manual-driven therapy 
has been extensively trialled as a strategy to improve treatment efficacy. However, the UK 
National Institute for Health and Care Excellence (NICE) endorses only behavioural 
reinforcement ('contingency management' [CM]), behavioural couple and family interventions, 
and 12-Step-based groups [13]. A subsequent Cochrane review of 13 different interventions 
was pessimistic, concluding that OAT effectiveness is not enhanced by the addition of any PSI 
support [14]. Our focus has been on OAT-resistant patients — a prevalent but understudied 
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clinical population. The standard design for efficacy studies in the substance use disorders 
field has been for practitioners to follow a therapist manual, so that patients are offered a set 
progression of interventions. This has advantages for fidelity and internal validity of inferences 
about efficacy; however, it offers little flexibility to tailor treatment and adapt it to the patient's 
personal preference, subsequent response and evaluation.  
 
As an alternative, we developed a case formulation-driven approach to tailor behaviour 
change components for each patient [15]. Common in mental health treatment, a case 
formulation is a collaborative discussion to develop a working hypothesis of how a disorder is 
being maintained, focusing on cognitive, affective and interpersonal factors. This assessment 
(usually supplemented with information gathered from rating scales and clinical case 
conference) informs the selection of interventions. As treatment proceeds, the patient and 
therapist monitor review progress, adapt therapeutic components as required and update the 
formulation. This approach has not been used before in studies of adjunctive PSI during OAT.  
 
We report the results of a randomised controlled trial of the effectiveness and cost-
effectiveness of an adjunctive, case-formulation driven, PSI for treatment-resistant patients in 
on-going OAT.  
METHODS 
Study design, setting and participants  
In this pragmatic, parallel-group, open-label, randomised controlled trial (the Addiction 
Recovery Clinic [ARC] study), our aim was to determine the effectiveness of a personalised 
PSI adjunctive to on-going OAT, compared to OAT treatment-as-usual (TAU). The study was 
done at a specialist NHS community addictions service, operated by South London and 
Maudsley NHS Trust. ARC also included a subsidiary biomarker study of treatment response 
(results reported elsewhere).   
 
Eligible patients were adults aged ≥18 years, meeting criteria for opioid and/or cocaine 
dependence in the past 12 months (MINI international neuropsychiatric interview [16] for 
Diagnostic and Statistical Manual of Mental Disorders-IV [DSM-IV] [17]; opioid use disorder 
(OUD) and cocaine use disorder for consistency with contemporary DSM-5 terminology), 
voluntarily seeking continued oral maintenance OAT with oral methadone, sublingual 
buprenorphine, or sublingual buprenorphine-naloxone.  
 
At study enrolment, we set six weeks as the minimum duration of OAT in the current episode, 
with no upper limit. All participants were classified as non-responders by structured interview 
(Treatment Outcome Profile [TOP] [18]) on the basis of the patient’s report of opioid and/or 
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cocaine use on one or more day in the past 28 days (verified by positive urine drug screen 
[UDS]). Otherwise eligible patients were excluded if they had a suicide plan in the past month 
or an attempt in the past six months; medically uncontrolled health conditions; current legal 
proceedings risking incarceration; or if they had participated in a substance use disorder 
treatment intervention study in the past six months.  
 
Potential participants were identified via the service’s electronic patient case record. They 
were told the purpose of the study was to determine the effectiveness of a PSI for people in 
OAT who wanted help to abstain from opioids and/or cocaine. Patients interested in the study 
attended the service to receive written information, complete screening and give their written 
informed consent.  
 
Ethical approval for the study was granted by the UK Health Research Authority (London-
Bromley Research Ethics Committee: 13/LO/0640). Details of the study protocol and PSI have 
been published [19]. In this article, the research procedures, clinical interventions and results 
are reported following the CONSORT extension for pragmatic trials [20]; the TIDieR guideline 
for complex interventions [21]; and the CHEERS guideline for cost-effectiveness evaluations 
[22]. 
 
Randomisation and masking 
Following baseline data collection, participants were randomly allocated (1:1) to the PSI or 
TAU group, with stratification by OAT medication (methadone or buprenorphine), and any use 
of cocaine, or illicit drug injecting in the past 28 days. The King’s College London Clinical 
Trials Unit developed and managed a web-accessed, password-protected randomisation 
sequence, with random permuted blocks of size two or four. After each participant-to-group 
allocation, the randomisation system issued a confirmatory email and the participant was 
immediately informed. Due to the open-label nature of OAT and PSI in this pragmatic trial, it 
was not feasible to mask participants, clinicians or the independent research assistants to 
group allocation.  
 
Procedures 
After consent, all participants attended a research assistant-administered, face-to-face, 60-
minute baseline interview. This included a calendar-prompt (‘time-line follow-back’) procedure 
in the TOP to record opioid and cocaine use in the past 28 days, and completion of the 
following instruments and procedures:  
 
(1) Montreal Cognitive Assessment (MoCA, version 7.1; score range: 0-30; ≥26 is the cut-off 
for current normal functioning [23]);  
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(2) the 9-item depression version of the Patient Health Questionnaire (PHQ-9; score range: 0-
27; ≥10 is the cut-off for moderate level symptoms during the past two weeks [24]);  
 
(3) the 7-item Generalized Anxiety Disorder Scale (GAD-7; score range: 0-21; ≥10 is the cut-
off for moderate level symptoms during the past two weeks [25]);  
 
(4) the Work and Social Adjustment Scale (WSAS; impairment attributed to opioid and/or 
cocaine use disorder; score range: 0-40; ≥10 is the cut-off for social functioning impairment 
during the past two weeks [26]);  
 
(5) the three-level version of the EuroQol measure of health-related quality of life (EQ-5D-3L) 
for the calculation of quality adjusted life years (QALYs) [27]; and 
 
(6) A tamper-proof, instant result UDS device with temperature sensor (Integrated E-Z Split 
Key Cup; www.concateno.com) to detect for morphine (opioids) and benzoylecgonine 
(cocaine's primary metabolite) with 300ng/ml detection sensitivity.  
 
Prior to treatment in the PSI group, a 90-minute assessment and case formulation were done 
by a senior psychologist (accredited by the British Association of Behavioural and Cognitive 
Psychotherapy [BABCP]) and an assistant psychologist. Shorter assessment appointments at 
the clinic were arranged for a minority of participants (e.g. those with depression). We used a 
patient-centred communication style and charts of relationships and supports [28]. All case 
formulation and clinical team discussions were completed in a maximum of six weeks. 
Treatment plans were reviewed weekly in a case conference attended by all therapists and 
the senior clinicians in the study.   
 
We assembled a toolbox of psychological change methods including: CBT for craving skills 
and behavioural experiments to modify disorder maintaining beliefs [29]; CM to reinforce 
abstinence, recovery activities and clinic attendance using retail store vouchers as the 
reinforcer [13]; 12-step group facilitation [30]; Behavioural Activation for depression [31]; and 
techniques to engage partners and family members in the participant's treatment [32]. The 
case formulation, MoCA total score and the PHQ-9, GAD-7 and WSAS items and total score 
were used to inform the content of the PSI and all participants were encouraged to select one 
of the three CM behavioural targets.  
 
The PSI was designed for completion in 12 weeks to coincide with most discrete 
psychotherapies recommended by NICE. However, we decided to optionally allow two 
additional weeks to replace any treatment sessions missed due to hospital attendance, police 
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custody, or therapist absence. Each session was weekly, face-to-face, for 60 minutes; with an 
option for 30-minute sessions twice-weekly to help attention for participants with depression.  
 
The PSI assistant psychologists were graduates or had a master’s degree. They received 
fortnightly individual supervision and weekly group supervision with senior psychologists. PSI 
sessions were audio-recorded with consent. An independent BABCP-accredited consultant 
psychologist rated a random five percent of these recordings for therapist competence on the 
12-item Cognitive Therapy Scale-Revised (CTS-R) [33]. On each item, a score of ≥3 indicated 
competent practice. 
 
All participants had scheduled fortnightly individual appointments (~30 minutes) at the service 
with their keyworker for drug counselling. Adjustments to medication dose were made during 
periodic medical review. Participants in the TAU group were not offered any additional 
intervention.  
 
Research assistant-administered interviews to record drug use and UDS data were scheduled 
at 6, 10, 14 and 18-weeks post-randomisation. For each visit, participants received public 
transport travel support and £20 in retail store vouchers for completing research measures. In 
our clinical experience, some patients in OAT leave for many weeks but then re-present 
requesting that their medication is re-started. Rather than accept low attrition, we anticipated a 
long duration of follow-up for some participants. 
 
Outcomes 
The primary outcome was treatment response status at 18 weeks post-randomisation after the 
12 to 14-week PSI. Treatment responders were defined as those who: (1) reported no use of 
opioids or cocaine during the 28 days prior to the final follow-up interview and (2) provided 
one or more negative UDS tests for heroin and cocaine in the 28 days prior to final follow-up 
and no positive tests. We judged that this biochemically-verified measure of abstinence was 
an appropriate and clinically meaningful indicator for patients who were retained, but not 
responding to OAT.  
 
At 18 weeks post-randomisation, participants defined as non-responders reported opioid 
and/or cocaine use on one or more days in the past 28 days or had incongruent self-report 
and UDS data (i.e. they reported total abstinence, but their UDS result indicated use of 
opioids, cocaine or both). Conservatively, all missing clinical visits for a scheduled UDS 
procedure were imputed positive for opioid and cocaine use.  
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Secondary outcomes (recorded at baseline and 18-week follow-up) were: the number of 
abstinent days for opioids and cocaine in the past 28 days recorded by TOP; retention in 
treatment (defined as the number of days from randomisation to the endpoint or exit);  
treatment adherence (operationalised as attendance at one-third or more scheduled 
sessions); mean scores on the MoCa (alternate version at follow-up), PHQ-9, GAD-7, WSAS 
and EQ-5D-3L; and mean costs of service use measured using a version of the Adult Service 
Use Schedule (AD-SUS) developed for drug and alcohol use disorder populations, described 
below. 
 
All adverse events — recorded by seriousness and likely relationship to the study — were 
reviewed by the senior investigators and the DMC.  
 
Statistical Analysis 
Our sample size calculation was based on the NICE Clinical Guideline 51 meta-analysis of 
adjunctive PSI during OAT with opioid abstinence as the outcome [13]. Taking an 18% 
difference in abstinence for the PSI (an RR of 1·75), and with 16% inflation for attrition (a rate 
of drop-out after six months of OAT in English specialist clinics [8]), we estimated that 368 
participants recruited would give 90% power to detect a group difference, with a two-sided, 
five percent alpha. The statistical analysis plan was agreed with the Trial Management Group, 
the Data Monitoring Committee (DMC), and the Trial Steering Committee and summarised in 
the published protocol [19]. All reported analyses were conducted in accordance with the 
published protocol, with no changes made except that log time was used in the model (see 
section on ‘analysis of the primary outcome’). The analysis of effectiveness was by intention-
to-treat (ITT).  
 
Stata (version 14·1) was used for all clinical and economic analyses. For the primary 
outcome, we estimated the group difference in binary responder status at each assessment 
point using a mixed-effects, maximum likelihood logistic regression model (command: 
meqrlogit). This included randomisation group, the study stratification factors and time of the 
assessments (days post-randomisation, both linear and quadratic log time) as covariates. We 
fitted a group x time interaction term to estimate treatment effects 18 weeks post-
randomisation, with a participant-varying random intercept to account for correlation between 
repeated measures on the same participant. 
 
Time-specific estimates of treatment effect (expressed as log-odds) were obtained as 
functions of model coefficients (command: lincom) with 95% CI based on the parameter 
covariance matrix. The delta method was used to calculate CI for absolute proportions. 
Differences in log-odds were displayed by post-estimation, with time and group covariates 
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fixed (command: margins). A sensitivity analysis was done to determine the robustness of 
outlying assessments included in the effectiveness model by removing endpoint assessment 
data collected 24 weeks post-randomisation.  
 
The analysis of the secondary outcome measures was done using a generalised, repeated 
measures, linear mixed-model framework with the following covariates: randomisation group, 
baseline score of the outcome measure, stratification factors, time of the assessment, and a 
group x time interaction term. For an adjusted treatment effect, we calculated Cohen's d effect 
size (ES) using the within-group pooled standard deviation (SD). Between treatment retention 
was evaluated using an unadjusted and adjusted Kaplan-Meier survival estimate and a log-
rank test of equality between groups. Personal social services included services provided by 
local authorities including accommodation, day care and drop in centres. 
 
Costs and cost-effectiveness  
We took a broad societal perspective, including NHS and personal social services 
(NHS/PSS), productivity losses (time off work due to illness), and criminal activity — the latter 
important for treatment research on substance use disorder [34]. The impact of treatments on 
crime is recognised by NICE as an appropriate extension to the NHS/PSS perspective for 
drug treatment evaluation [35]. Personal social services included services provided by local 
authorities including accommodation, day care and drop-in centres. 
 
Our pre-specified primary economic evaluation assessed cost-effectiveness in terms of the 
primary clinical outcome at 18-weeks converted to an average marginal effect. This expressed 
the probability of a positive treatment response. With a broad societal perspective, we did a 
secondary evaluation of cost-effectiveness in terms of QALYs, derived from the EQ-5D-3L. 
Sensitivity analyses explored cost-effectiveness based on the NICE reference case, with 
QALYs and the narrower NHS/PSS perspective [35]. The health states described in the EQ-
5D-3L were assigned a utility weight or score using responses from a representative sample 
of adults in the UK [36]. These weights were applied to the time between interviews and 
QALYs calculated by area-under-the-curve. 
 
The version of the AD-SUS in the current study (available from the authors on request) 
included a section with questions about crimes committed by, and against, participants. We 
also collected data on the use of the PSI intervention, keyworker sessions and collated 
methadone and buprenorphine prescriptions from the electronic patient record.  
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We applied unit costs (see Tables S1-S3 in the Appendix), for the 2015/16 financial year, 
uprated where necessary using the Hospital and Community Health Services Index [37]. 
Discounting was unnecessary because the follow-up period was less than 12 months.  
 
We costed the PSI using a standard micro-costing approach [38]. Therapist salary costs 
included employer costs (national insurance and superannuation) and overheads (buildings, 
management, administration and utilities). We adjusted for indirect time using questionnaires 
completed by therapists and keyworkers on the ratio of direct to indirect time (i.e. face-to face 
contact, and therapy preparation, notes, supervision, and training). National unit costs were 
applied to all other health and social care services [39], OAT medication [40], and criminal 
activity. We took a human capital approach to value productivity losses [41].  
 
All economic analyses included adjustment for study stratification factors and baseline values. 
Mean cost differences were analysed by t-test, with bias-corrected non-parametric 
bootstrapping. We imputed missing cost and outcome data with multiple imputation using 
chained equations, under the assumption that these data were missing-at-random. Variables 
used in the multiple imputation model included the stratification factors, duration of follow up, 
baseline outcome score and baseline costs.  
 
Cost-effectiveness was explored in two steps. First, we calculated incremental cost-
effectiveness ratios by dividing the difference in mean costs between the two groups by the 
difference in mean outcomes. Then we explored uncertainty around these point estimates 
using scatterplots of bootstrapped incremental mean cost and group outcome differences and 
cost-effectiveness acceptability curves. This indicated the probability that each treatment is 
the optimal choice for different values of willingness-to-pay (WTP) for a unit improvement in 
the probability of treatment response (a nominal £0 to £1,000 per one percentage point 
increase), and £0 to £30,000 per QALY, as preferred by NICE [35].  
 
This trial is registered with the ISRCTN registry, number ISRCTN69313751. 
 
Role of the funding source 
The funder for the ARC trial had no role in the study design, data collection, analysis and 
interpretation, or report writing. The corresponding author had full access to all study data and 
took final responsibility for the decision to submit for publication.  
RESULTS 
Participants were recruited between June 7, 2013 and December 21, 2015. The trial database 
was locked for analysis on April 19, 2017 ending the study. 348 patients were assessed for 
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eligibility (15 [4%] ineligible and 60 [17%] declining to participate). 273 participants gave their 
signed consent and were randomised: 137 (50%) to the TAU group and 136 (50%) to the PSI 
group. The trial profile is shown in Figure 1.  
 
Three patients who were allocated to the TAU group and completed the study, re-presented to 
take part again at a screening session administered by a different worker. All three patients 
did not declare that they had been in the study before. In error, the worker did not properly 
check the participant list and these patients were randomised again: one allocated to the PSI 
group and two allocated to the TAU group. The patient allocated to the PSI group was 
detected before the start of their case formulation. The three patients were informed of the 
error and continued in their original allocation of TAU. We consulted the DMC and published 
guidance [42]. These cases are included in the trial flow and tabulated sample characteristics, 
but they were removed from all subsequent analysis. The remaining 270 participants formed a 
modified ITT population (mITT).  
 
Between group allocation and the start of the PSI, 12 participants withdrew from the PSI group 
and 13 participants withdrew from the TAU group. After the intervention began three 
participants withdrew from the PSI group, and five withdrew from the TAU group. All of these 
participants gave their consent for all data collected to be used in the analysis.  
 
Participant and clinical characteristics were well balanced between groups (Table 1). All 
participants met diagnostic criteria for OUD or cocaine use disorder. Overall, in the 28 days 
before study enrolment (n=273), 250 (92%) used opioids; 228 (84%) used crack cocaine (a 
minority used powder cocaine: 26 [9·5%]), and 89 (33%) injected drugs. The sample had been 
enrolled in a current OAT episode for a median of 25·50 weeks (IQR 10-88).  
 
Treatment exposure and fidelity  
At the endpoint, 125 (93%) of 135 participants in the PSI group and 124 (92%) of 135 of 
participants in the TAU group were receiving OAT at the clinic. There were no clinically 
meaningful group differences in methadone or buprenorphine dose. In the PSI group, 
participants on methadone were prescribed 57·2 mg/day, and those on buprenorphine were 
prescribed 11·5 mg/day. In the TAU group, participants on methadone were prescribed 59·3 
mg/day and those on buprenorphine were prescribed 10·7 mg/day. Across the study, the PSI 
was delivered by five assistant psychologists. Each assistant psychologist was independently 
rated as competent on the CTS-R. 
 
Analysis of the primary outcome 
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Overall, the median time to the endpoint interview was 19·4 weeks (IQR 12·7 to 121·0), with 
10 participants interviewed between 50 and 121 weeks. The median time to endpoint in the 
PSI group was 22·9 weeks and 18·0 weeks in the TAU group. Due to the unforeseen long 
duration of follow-up, we decided to use log time from randomisation in all analyses, finding 
that a quadratic term improved model fit. Models were estimated using maximum likelihood 
with inferences judged under the assumption that the missing data generating mechanism 
was missing-at-random. Deviation from missing-at-random was accounted for by including 
variables that were predictive of missingness in the model. The number of days of opioid use 
at baseline was predictive of missing data, so this measure was also included in the model. 
 
Table 2 shows the frequencies and Figure 2A shows the model-estimated group differences 
at each follow-up to endpoint. No participant refused to comply with a UDS procedure. At the 
endpoint, there were 22 (16·3%) of 135 participants in the PSI group and 9 (6·7%) of 135 
responders in the TAU group (adjusted log odds 1·20, 95% CI 0·01 to 2·37, p-value=0·048.  
 
Figure 2B displays shows a marginal effects plot of the magnitude of the absolute 
proportions. The predicted probability of being a treatment responder at primary endpoint was 
0·091 in the TAU group and 0·171 in the PSI group.  
 
With removal of endpoint assessment data after 24 weeks for the sensitivity analysis, we 
estimated stronger evidence of effectiveness for the PSI (adjusted log odds 2·31, 95% CI 0·62 
to 4·00, p-value=0·007). 
 
Analysis of secondary outcomes 
Compared to the TAU group, the PSI group reported more opioid abstinent days (ES 0·39, 
95% CI 0·15 to 0·62, p-value=0·001) and crack cocaine abstinent days (ES 0·27, 95% CI 0·27 
to 0·47, p-value=0·009). There was no group difference in abstinence from cocaine powder 
(ES 0·12, 95% CI -1·13 to 0·36, p-value=0·344).  
 
Figure 2D displays the Kaplan-Meier plot for retention in treatment. There was no group 
difference in retention, either unadjusted (χ2[1] = 1·20, p-value = 0·270) or after adjusting for 
study covariates (χ2[1]  = 0·26, p-value = 0·610).  
 
For keyworker contact, 99·3% of the PSI group and 92·6% of the TAU group attended the 
clinic to receive general counselling and support once or more. The PSI group attended 8·8 
scheduled keyworker appointments (SD 5·4, range: 1-33). The TAU group attended 7·5 
scheduled keyworker sessions (SD 5·1, range: 0-28). Participants in the PSI group attended 
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an average of 4·9 sessions (SD 4·9, range: 0-20). 79 (58·5%) attended more than one-third of 
their scheduled sessions and were classified as adherent.  
 
There was a reduction in OUD-attributed social impairment on the WSAS (ES 0·27, 95% CI 
0·04 to 0·50, p-value=0·016), but no group difference in cognitive function, depression or 
anxiety symptoms (Table 2 and Figure 2C).  
 
Economic Analysis  
Complete economic data were available for 95 (70·4%) of 135 participants in the PSI group, 
and for 104 (77·0%) of 135 participants in the TAU group. Table S4 in the Appendix shows  
mean resource use in both groups over the follow-up period. Patients in the PSI group 
attended an average of five therapy sessions and almost all participants continued to attend 
drug keyworker sessions, regardless of group allocation. There was little difference between 
groups in the number of keyworker sessions attended (approximately eight sessions per 
participant) or the proportion attending (approximately 98%). The use of secondary care, 
primary care and social care services was broadly similar across the two groups, although the 
PSI group spent a greater number of nights in hospital on average. Average doses of 
methadone and buprenorphine were broadly similar. There was little difference in the 
proportion of the groups reporting criminal activity over the follow-up period. Differences in 
absenteeism from work were small, with 26% of employed participants in both groups 
reporting days off work.  
 
Table S5 in the Appendix shows disaggregated imputed mean costs during follow-up 
alongside tests for differences including multiple imputation and adjustment for pre-specified 
variables. OUD intervention costs were significantly higher in the PSI group (mean difference 
£561, SE £60, 95% CI £443 to £680, p-value<0·001), but this was off-set by lower costs of 
criminal activity among the participants in the PSI group (mean difference -£1,843, SE £3,109, 
95% CI -£8,127 to £4,442, p-value=0·557). There was no significant difference in societal 
costs between the TAU and PSI groups (mean difference -£400, SE £3,416, 95% CI -£7,274 
to £6,475, p-value=0·907) or in total NHS/PSS costs between the two groups (mean 
difference £658, SE £876, 95% CI -£1,070 to £2,388, p-value=0·453).  
 
The probability of treatment response was significantly higher in the PSI group compared to 
the TAU group (average marginal effect 0·108, SE 0·048, 95% CI 0·012 to 0·238, p-
value=0·025). QALYs were also significantly higher in the PSI group than TAU (mean 
difference 0·048, 95% CI 0·016 to 0·080, p-value=0·004) in adjusted analyses with missing 
data imputed. Complete case EQ-5D-3L values and QALYs are summarised in Table S6 in 
the Appendix. The average value at baseline was slightly higher in the PSI group (0·674) 
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compared to TAU (0·649). At follow-up, the average values had declined in both the PSI 
group (-0·014) and TAU (-0·080).  
 
For the primary outcome, Figure 3 displays a scatterplot of bootstrapped cost and 
effectiveness pairs for PSI versus TAU with effectiveness measured in terms of treatment 
response. This shows points falling primarily in the North-East quadrant (PSI more effective 
and more expensive than TAU) and the South-East quadrant (PSI more effective and cheaper 
than TAU), with the point estimate and 87% of scatter points falling below the £1,000 per one 
percentage improvement in the probability of the cost-effectiveness threshold line. The 
corresponding cost-effectiveness acceptability curve (Figure S1 in the Appendix) shows that 
the probability that PSI was cost-effective compared to TAU was greater than 50% at WTP 
levels of £30 or higher per one percentage point improvement in the probability of treatment 
response (range 47% at a WTP level of £0 to 87% at a WTP level of £1,000).  
 
For QALYs, Figure S2 (in the Appendix) shows the scatterplot of bootstrapped cost and 
QALYs for PSI versus TAU. The probability that PSI was cost-effective compared with TAU 
was 60% and 67% at the NICE WTP thresholds of £20,000 and £30,000 per QALY (Figure 
S4 in the Appendix).  
 
The sensitivity analysis based on the NICE reference case, using QALYs and taking the 
NHS/PSS perspective was less favourable than the societal perspective, due to the exclusion 
of the cost of criminal activity. However, while the probability of PSI being cost-effective 
compared to TAU was only 36% at the NICE threshold of £20,000 per QALY, the probability 
was 56% at the NICE threshold of £30,000 per QALY (Figure S4 in the Appendix). 
 
Adverse events   
In total, 38 of 273 (13·9%) participants reported an adverse event: 20 of 136 (14·7%) in the 
PSI group, and 18 of 137 (13·1%) in the TAU group (χ2[1] =0·487, p-value=0·490) (Table 3). 
There were three severe adverse events: in the TAU group, 1 [1%] of 136 died after hospital 
admission for drug injection-related sepsis, and 1 (1%) of 136 was hospitalised after head 
injury and later discharged. In the PSI group, 1 (1%) of 137 was hospitalised after a panic 
attack and later discharged. None of the severe adverse events was judged to be trial-related.  
DISCUSSION 
Among OAT-resistant patients in the ARC trial, approximately 16% of the group allocated to 
receive an adjunctive, case-formulation driven, personalised PSI achieved the endpoint 
defined measure of treatment response (i.e. biochemically-verified, self-reported abstinence 
from opioids and cocaine in the previous 28 days), compared to 7% of the group receiving 
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TAU. Participants in the PSI reported more opioid and crack cocaine abstinent days (ES 0·39 
and ES 0·27, respectively), and had less social impairment (ES 0·27).  
 
The PSI also represented good value for money, with better outcomes and lower total costs 
per participant compared to TAU. The probability that the PSI was cost-effective compared to 
TAU was 60-67% at the NICE willingness to pay thresholds of £20,000 to £30,000 per QALY. 
It was also cost-effective from the narrower NHS/PSS perspective but only at the upper NICE 
threshold. However, NICE has acknowledged that reductions in crime due to drug treatment 
programmes, as observed in this study, are an appropriate extension to the recommended 
NHS/PSS perspective [36]. Our study suggests that the economic benefits of addiction 
treatment are largely accounted for by reduced crime and victim costs of crime. 
 
Previous studies of PSI have included a sample of patients with OUD in methadone or 
buprenorphine maintenance therapy at admission, or after some period of treatment; so a 
major strength of the ARC study is the focus on patients who were not responding after 26 
weeks in treatment. It is also usual for intervention trials to evaluate OST on a single measure 
of opioid use. We believe our inclusion of cocaine alongside opioid use in the definition of the 
primary outcome measure was a strength, because the likelihood of abstaining from opioids 
during OAT has been consistently shown, in our public treatment system and elsewhere, to be 
strongly moderated by cocaine use.   
 
We were able to recruit a high proportion of patients screened (78%) and at enrolment, the 
study groups were well-balanced on demographic and clinical characteristics. Reflecting the 
current standard profile of OAT at specialist OUD treatment services in England, 
approximately two-thirds of our sample were enrolled in methadone maintenance treatment 
and one-third was enrolled in buprenorphine maintenance treatment. Importantly, 93% of the 
PSI group were receiving OAT at the end of the study (no group difference). There were also 
no clinically important differences in medication dose at the endpoint or levels of keyworker 
contact, so it was it unlikely that fluctuations in medication accounted for our findings. 
 
The success of our aim to motivate patients to engage in a PSI was reflected in the rate of 
attendance at the level set to indicate adherence: one-third or more therapy sessions (59%). 
This compares reasonably well to other studies (e.g. 48% non-attendance for first session of 
individual psychological therapy [42], and 34% commencing but then not attending [43]). In 
many treatment systems, clinical psychologists and psychotherapists in substance use 
disorder services are in short supply, so another key strength of the study is that we were able 
to train and supervise psychology assistants to deliver an effective PSI, all of whom were 
rated competent. Although it took many weeks to complete field-work, there was a relatively 
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low level of loss to follow-up and all participants who withdrew from the study gave their 
consent for their data to be used in the analysis.  
 
ARC trial findings must be interpreted in the light of several limitations. Firstly, the number of 
patients interested in taking part in the study was over-estimated, and our achieved sample of 
273 participants fell short of the 368 target. However, we powered the trial conservatively at 
90% for the primary outcome. Second, the rate of effectiveness for our PSI was less than 
anticipated (18% difference in abstinence). The rate of treatment response was 16·3% in the 
PSI group and treatment response rate and 6·7% in the TAU group (adjusted log odds 1·20, 
95% CI 95% CI 0·01 to 2·37). We believe this is a clinically meaningful finding, not least 
because our primary outcome was stringent, requiring UDS-verified self-reported abstinence 
from both opioids and cocaine to define a positive outcome response. Also, our perseverance 
to secure endpoint interviews was conservative for the estimate of PSI effectiveness because 
there was a tendency for those with long follow-up times to be identified when they re-
presented for further OAT following relapse (so none achieved the primary outcome 
measure).  
 
When we removed endpoint assessment data after 24 weeks for a sensitivity analysis, our 
estimate of positive evidence for the PSI almost doubled (adjusted log odds 2·31, 95% CI 
0·62 to 4·00). There is, however, no doubt that the ARC trial highlights the challenge facing 
clinicians to engage patients who are retained in OAT but continue to use opioids and 
cocaine. Our findings set a level of expectation for future studies with this population. In the 
PSI group, many participants were motivated to attend a formulation assessment and to try 
out cognitive and behavioural interventions. However, for a small number of participants, it 
proved very challenging to engage with them after one or two sessions (results of our case 
formulation and psychological intervention selection process are reported elsewhere). 
 
Third, we were not able to blind research assistants to study group. However, the primary 
outcome included a biochemical verification component, and this was supported by a 12-point 
increase in the ES for the opioid and cocaine abstinence collected via a field-standard 
structured interview. It was unfortunate that three patients who indicated interest in joining the 
study for a second time were not properly checked; but we identified this problem quickly, 
instituted preventive training, and our DMC-recommended mITT analysis strategy was 
conservative.  
 
Fourth, ARC is a single-centre trial and we do not know the extent to which the findings 
reported here will generalise to other clinics prescribing medication for OUD. This was a 
pragmatic study done in a routine NHS clinical setting with minimal participant exclusion 
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criteria and we believe our comparator (medical management and fortnightly 30-minute drug 
counselling) is comparable to that offered by community treatment services in England. We 
have shown that a team approach with supervised psychology assistants is cost-effective and 
our findings lend support to this investment by treatment services.  
 
As has been long observed in psychotherapy, the addition of an ingredient to standard care is 
likely to achieve only a small average effect [45]. This is reflected in the current position of the 
NICE that CBT should not be offered routinely to those receiving OAT [13; page 148].  
This recommendation is based on the average treatment effect from samples recruited at 
admission or during treatment — thereby mixing current treatment responders and non-
responders — and potentially masking PSI efficacy for responders. However, we have shown 
that a personalised PSI can be effective when targeted to non-responders, so in that sense 
we agree with the NICE’s recommendation not to offer a CBT-type PSI routinely. A 
personalised approach in which specific behaviour change interventions are tailored to need 
could well prove to be a fruitful strategy for evidence-based therapeutics in addiction.  
 
We did not observe a reduction in anxiety and depressive symptoms. Further analysis will be 
published elsewhere, but it appears that additional interventions may be needed. Clinical 
responders to OAT should also not be overlooked. They may be completely abstinent but 
amenable to relapse prevention-oriented PSI and support to attain other goals such as 
employment.  
 
Disaggregation of the OUD clinical population is also important. There is evidence that non-
responders are visible early in treatment. A US trial found that 26·4% of the sample did not 
stop opioid use after two weeks of buprenorphine maintenance therapy, with this non-
response strongly predictive of opioid use three months later [46]. A significant minority of 
patients will also stay in treatment over the longer-term and continue to use opioids or relapse. 
A recent study of 7,719 patients who were continuously enrolled in OAT for five years [47], 
found that one-seventh displayed a stable pattern of non-response (opioids used on 15 of the 
past 28 days prior to six-monthly clinical reviews across 5·5 years). But even if drug use is not 
suppressed, the offer of a PSI should be kept open while the patient benefits from a reduced 
risk of fatal opioid-related overdose and help to receive other medical services as needed.  
The applied conclusion from this study is that clinicians providing OAT should assess their 
patients' response early once the maintenance dose has been achieved. If OAT is not giving 
clinical benefit, even a basic case formulation will shed important light on the reasons why and 
point to an intervention. We also believe there is much to be gained from using clinical scales 
where these provide actionable information and inform the process of selecting change 
methods. Clinicians should bear in mind that the patient's personal preferences are key, so 
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having a toolbox of psychological change methods gives flexibility and the ability to adapt 
treatment according to the patient's response and evaluation.  
 
An integrated approach to assessment, stratified treatment and continuing care is now gaining 
momentum in behavioural medicine, where tailoring variables and decision rules is improving 
outcomes. At present, there is relatively limited evidence for this measurement-based care 
approach to adapt interventions in the substance use disorders field [48]. The ARC trial has 
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Table 1: Sample characteristics at baseline 
 
Patient characteristics PSI (n=136) TAU (n=137) All (n=273) § 
  Age, years 43·1 (7·8) 42·6 (7·8) 42·8 (7·8) 
  Sex    
    Male 103 (75·7%) 102 (74·5%) 205 (75.1%) 
    Female 33 (24·3%) 35 (25·5%) 68 (24·9%) 
  Ethnicity    
    White  96 (70·6%) 105 (76·6%) 201 (73·6%) 
    Black 18 (13·2%) 17 (12·4%) 35 (12·8%) 
    Other 22 (16·2%) 15 (11·0%) 37 (13·6%) 
Employment status    
  In full or part-time work 20 (14·7%) 9 (6·6%)  29 (10·6%) 
  Not working  116 (85·3%) 128 (93·4%)  244 (89·4%) 
Opioid agonist treatment (OAT)    
  Methadone ¶ 93 (68·4%) 93 (67·9%)  186 (68·1%) 
  Methadone dose, mg/day 55·6 (20·0) 56·2 (24·8)  55·9 (22·5) 
  Buprenorphine ¶ 43 (31·6%) 44 (32·1%)  87 (31·9%) 
  Buprenorphine dose, mg/day  12·0 (5·2) 10·7 (5·3)  11·3 (5·2) 
Weeks of OAT at study enrolment † 26 (9-89) 25 (11-88) 26 (10-88) 
Substance dependence *    
  Opioid **  118 (86·8%) 115 (83·9%)  233 (81·7%) 
  Cocaine   94 (69·1%) 96 (70·1%)  190 (69·6%) 
Drug use in past 28 days ‡    
  Opioid (illicit or non-prescribed) 124 (91·2%) 126 (92·0%)  250 (91·6%) 
  Crack cocaine ¶ 114 (83·8%) 114 (83·2%)  228 (83·5%) 
  Cocaine powder 14 (10·3%) 12 (8·8%)  26 (9·5%) 
  Illicit drug injecting ¶ 43 (31·6%) 46 (33·6%)  89 (32·6%) 
Urine Drug Screen (positive test)    
  Morphine (opioid) 116 (85·3%) 115 (83·9%) 231 (84·6%) 
  Cocaine (benzoylecgonine) 103 (75·7%) 107 (78·1%) 210 (76·9%) 
  Benzodiazepine 28 (20·6%) 38 (27·7%) 66 (24·2%) 
 
 Data are mean (SD) or n (%); or † median (IQR). 
 TAU = treatment as usual; PSI= personalised psychosocial intervention. 
 § includes three participants re-randomised in error, who were then deleted from all  
  analysis of clinical and cost-effectiveness.  
 ¶ Stratification variable. 
 *  DSM-IV (past 12 months) 
 ** remaining cases in each group in remission for opioid dependence. 





Table 2: Primary and secondary outcomes at 18 weeks 








Primary outcome      
 Baseline - -   
  6-weeks 8/80 (10·0%) 6/84 (7·14%) -  
 10-weeks  7/49 (14·3%) 4/50 (12·0%) -  
 14-weeks  6/21 (28·57%) 0/15 (0%) -  
 18-weeks (endpoint)  22/120 (18·3%) 9/117 (7·6%)  1·20 (0·01 to 2·37) ¶ 0·048 
Secondary outcomes §     
 Opioid PDA      
  Baseline 52·49 (36·47) 49·92 (35·15) -  
  Endpoint 72·62 (32·85) 56·78 (37·75) 13·62 (5·84 to 21·40) § 0.001 
 Crack cocaine PDA      
  Baseline 59·95 (36·13) 56·43 (38·03) -  
  Endpoint 78·98 (29·85) 67·34 (35·40) 8·74 (2·20 to 15·28) § 0.009 
 Cocaine powder PDA      
  Baseline 98·94 (3·95) 99·15 (3·89) -  
  Endpoint 99·26 (3·52) 98·32 (10·70) 0·93 (-1·10 to 2·96) § 0.344 
 MoCA      
  Baseline 22·28 (4·47) 21·20 (4·77) -  
  Endpoint 22·93 (3·70) 22·36 (4·51) -0·16 (-1·06 to 0·74) § 0.724 
 PHQ-9      
  Baseline 14·01 (7·73) 14·04 (7·29) -  
  Endpoint 10·91 (7·21) 12·34 (8·11) 1·33 (-0·36 to 3·01) § 0.136 
 GAD-7     
  Baseline 9·84 (6·37) 10·12 (6·60) -  
  Endpoint 8·73 (6·03) 10·03 (7·17) 1·15 (-0·26 to 2·56) § 0.114 
 WSAS      
  Baseline 22·35 (10·20) 21·12 (11·06) -  
  Endpoint 16·46 (12·64) 19·19 (12·60) 3·42 (0·53 to 6·32) § 0.016 
 
Data n (%), mean (SD) or mean (95% CI). TAU = treatment as usual; PSI= psychosocial 
intervention; PDA = percent days abstinent in past 28 days; MoCA = Montreal Cognitive 
Assessment; PHQ-9 = Patient Health Questionnaire; GAD-7 = Generalized Anxiety Disorder 
Scale; WSAS = Work and Social Adjustment Scale.  
 
† The referent group for between-group differences.  
 
¶ Adjusted odds ratio (95% CI) from mixed-effects logistic regression model, including OAT 
medication (coefficient [coef.]. 0·654, standard error [SE] 0·635, 95% CI -0·590 to 1·898, p-
value 0·303); baseline opioid use (coef. -0·085, SE 0·031, 95% CI -0·146 to -0·024, p-value 
0.006); baseline cocaine use (coef. -1·536, SE 0·696, 95% CI -2·900 to -0·172, p-value 
0.027); illicit drug injecting (coef. 0·654, SE 0·635, 95% CI -0·590 to 1·898, p-value 0.303); log 
time (coef. 5·719, SE 2·671, 95% CI 0·484 to 10·955, p-value 0.032); log time squared (coef. -
1·014, SE 0·500, 95% CI -1·995 to -0·034, p-value 0.043); and treatment x log time (coef. -
0·406, SE 0·205, 95% CI 0·004 to 0·807, p-value 0.048) 
 
§ Adjusted difference between baseline and endpoint for scaled measures from generalised, 
repeated measures, linear mixed-model framework, including covariates used in the model for 
the primary outcome. 
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Table 3: Adverse events by event 
 
Event/type PSI (n=136) TAU (n=137) 
Adverse Events (AE)   
Total number of AE (people) 22 (20) 19 (18) 
Haematological 0 1 
Musculo-skeletal 1 2 
Neurological 0 1 
Psychiatric 20 (18) 15 (14) 
Immunological 1 0 
Severe Adverse Events (SAE)   
Total number of SAE (people) 1 2 
Hospitalisation  1 1 





























































348 assessed for eligibility 
75 ineligible 
     60 declined to participate 
     15 did not meet inclusion criteria 
273 randomised 
136 allocated to PSI 
eligibility 
 2 excluded § 
137 allocated to TAU 
80 with data at 6-
week follow-up † 
  of intervention 
84 with data at 6-
week follow-up 
49 with data at  
  10-week follow-up 
101 had no data 
   99 did not attend for 
      assessment 
    2 withdrew ¶ 
      
74 with no data 
     73 did not attend for 
       assessment 
      1 withdrew ¶ 
 
       
50 with data at  
  10-week follow-up 
21 with data at  
  14-week follow-up 
120 with data at  
  18-week follow-up 
135 included in mITT 
  population  
  10 week follow-up 
117 with data at  
  18-week follow-up 
135 included in mITT 
population 
15 with data at  
  14-week follow-up 
102 had no data 
   101 did not attend for 
     assessment 
   1 died  
      
PSI = opioid agonist treatment with adjunctive personalised psychosocial intervention. All those with follow-up 
data attended PSI sessions. TAU = opioid agonist treatment-as-usual; mITT = modified intention-to-treat. 
 
¶ all withdrawn participants gave consent for their available data to be included in the analysis. 
§ case(s) re-randomised in error and excluded from all analysis. 
† start of PSI. 
  1 excluded § 
51 with no data 
     38 did not attend for 
       assessment 
      13 withdrew ¶  
  
       
55 with no data 
   43 did not attend  
        follow-up 
   12 withdrew ¶ 
 
       
51 with no data 
   38 did not attend  
        follow-up 
   13 withdrew ¶ 
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TAU = treatment as usual; PSI= personalised psychosocial intervention. 
PDA = percent days abstinent in past 28 days. 
 
Results are derived from fully adjusted mixed effects models controlling for stratification 
factors. 
Figure 2C are Cohen’s d standardised effect size estimates to allow comparisons between 
measures (increasing value indicates positive effect).  




Figure 3: Scatterplot showing bootstrapped mean difference in 
imputed costs and effects of PSI compared with TAU 
 
 
 TAU = treatment as usual;  
PSI= personalised psychosocial intervention. 













Figure 6 Scatterplot showing the bootstrapped mean differences in imputed total costs and treatment 









-0.3 -0.2 -0.1 0 0.1 0.2 0.3
Difference in cost 
Difference in response 
95% confidence ellipse 
 
£1000 per 1% improvement in response threshold line 
48% of scatter 
points in the 
NE quadrant 
PSI More effective PSI Less effective 
5% of scatter 
points in the 
NW quadrant 
4% of scatter 
points in the 
SW quadrant 
43% of scatter 

























Table S1: Unit costs of health and social care services  
 




Trial data – Table S2 
Trial data – Table S2 
£126 per contact hour 
£72 per contact hour 
Accommodation 
Staffed accommodation  PSSRU 2.2 Local authority care homes for people 
with mental health problems § 
£951 per week 
Hospital services 
Hospital drug services 
admission 
PSSRU 2016 2.1 Drug services – admitted (bed day) 
§ 
£359 per bed day 
Hospital mental health 
admission 
PSSRU 2016 2.1 Mental health care clusters (bed 
day) § 
£373 per bed day 
Non-elective inpatient long 
stay (>=5 days) 
PSSRU 2016 7.1 NHS reference costs § £2900 per episode 
Non-elective inpatient 
short stay (<5 days) 
PSSRU 2016 7.1 NHS reference costs § £616 per episode 
Outpatient appointments PSSRU 2016 7.1 NHS reference costs § £135 per attendance 
Accident & emergency  Department of Health Reference costs 2015-2016 ¶  £138 per attendance 
Ambulance PSSRU 2016 7.1 NHS reference costs § £238 per attendance  
Hospital pharmacist PSSRU 2015 13.6 Hospital pharmacist † £101* per contact hour 




PSSRU 201610.8b GP - unit costs ¶ £36 per 9.22 minutes 
General practitioner – 
home  
PSSRU 201510.8a GP - home visit † £90* per visit  
Practice nurse PSSRU 2015 10.6 Nurse/GP practice † £57* per contact hour  
District nurse PSSRU 2015 10.3 Health visitor † £77* per contact hour  
Community psychiatrist PSSRU 2016 15.7 Consultant – psychiatric § £138 per contact hour 
Community psychiatric 
nurse 
PSSRU 2015 10.2 Nurse (mental health) † £76* per contact hour 
Community mental health 
team (CMHT) 
PSSRU 2016 12.2 CMHT mental health team for 
adults with mental health problems § 
£38 per contact hour 
Occupational therapist PSSRU 2016 11.5 Community OT § £44 per hour 
Art therapy  Assumed equivalent to Community OT £44 per hour 
Accommodation 
keyworker 
PSSRU 2016 11.4 Social Work Assistant § £30 per hour 
Counsellor PSSRU 2015 3.4 Alcohol health worker † £57* per contact 
Family therapist   Assumed equivalent to counsellor £57 per contact 
Social worker PSSRU 2016 11.2 Social worker § £79 per hour 
Day care/drop-in centre PSSRU 2016 2.4 Local authority day care for people 
with mental health problems § 
£34 per client 
attendance 
Syringe exchange  Cost per pack  0.29 per pack 









Table S1: Unit costs of health and social care services, cont.../ 
 
Item Source Unit cost 





£3.96* per call 
Prison/police doctor Assumed equivalent to GP home visit £90 per visit 
Prison/police nurse PSSRU 2016 2.1 NHS Reference costs for mental 
health services – Prison health adult and elderly § 
£80 per contact 
Dentist PSSRU 2016 10.6 Dentist – providing-performer § £184 per contact hour 
Psychologist PSSRU 2014 9.5 Clinical Psychologist ‡ £139* per contact hour 
Group therapy, face to 
face 
PSSRU 2015 2.9 MBCT therapy – group-based 
interventions † 
£14* per person 
IAPT PSSRU 2016 2.1 NHS Reference costs for mental 
health services: Improving Access to Psychological 
Therapies § 
£96 per contact 
Dietician PSSRU 2015 13.4 Hospital dietician ‡ £39* per contact hour 
Medications 
Buprenorphine Drug Tariff (Part VIIIA Category M) price. 
URL: http://www.nhsbsa.nhs.uk/PrescriptionServices
/1821.aspx (accessed 24.10.18) 
Pack of seven 
 8mg £2.90 
Methadone Drug Tariff (Part VIIIA Category M) price, 
URL: http://www.nhsbsa.nhs.uk/PrescriptionServices
/1821.aspx (accessed 24.10.18) 
1mg/ml oral solution 
500ml £6.15 
Controlled drug 
supervised dispensing fee 
Methadone-Fees-Calculator-April-2013-interactive 
(Methasoft) Monthly fee for 14-day supervised 
prescriptions  
£31.96* per month 
Productivity losses 







§ Curtis L, Burns A. Unit Costs of Health and Social Care 2016, Personal Social Services 





† Curtis L, Burns A. Unit Costs of Health and Social Care 2015, Personal Social Services 
Research Unit. 2015. University of Kent, Canterbury. 
 
‡ Curtis L, Burns A. Unit Costs of Health and Social Care 2014, Personal Social Services 
Research Unit. 2014. University of Kent, Canterbury. 
 





Table S2: Cost of PSI therapist and TAU keyworker time  
Item Source Cost/time 
Therapist time   
A. Psychology Assistant salary Therapist time use questionnaire £25,622 
B. Employers NI and superannuation NI plus 14% pension contribution £5,835 
C. Overheads § Study site data £29,676 
D. Wages plus overheads (A+B+C) A+B+C £61,133 
E. Working time Hours per year ¶ 1,538 
F. Cost per hour D/E £39.75 
G. Cost per hour in direct client contact  Fx3.03 ratio of face-to-face to indirect time  £120.44 
H. Supervision/training/ preparation 
     cost per hour 
Four hours per week of clinical psychologist time £5.34 
Cost per minute in direct client contact G+H/60 minutes £2.10 
Keyworker time   
A. Keyworker salary Keyworker time use questionnaire £3,2114 
B. Employers NI and superannuation NI plus 14% pension contribution £7,575 
C. Overheads § Study site data £2,9676 
D. Wages plus overheads (A+B+C) A+B+C £69,365 
E. Working time Hours per year ¶  1,538 
F. Cost per hour D/E £45.10 
G. Cost per hour in direct client contact  Fx1.47 ratio of face-to-face to indirect time  £66.30 
H. Supervision/training/preparation  
     costs per hour 
Five hours per week of senior keyworker time £5.56 
Cost per minute in direct client contact G+H/60 minutes £1.20 
 
NI = National Insurance 
§ Including capital, administrative and managerial overhead costs. 














Table S3: Unit costs of crime 
Item  Source Unit 
cost* 
Burglary in a dwelling Brand & Price §  £4,399 
Burglary not in a dwelling  Dubourg, Hamed & Thorns ¶ £4,196 
Robbery of personal property Brand & Price § £9,803 
Robbery of commercial property Brand & Price § £9,803 
Theft of a vehicle Brand & Price § £5,570 
Theft from a vehicle Brand & Price § £1,155 
Theft of cycle Brand & Price § £853 
Theft from the person Brand & Price § £1,136 
Theft from shops Dubourg, Hamed & Thorns ¶ £155 
Handling stolen goods Dubourg, Hamed & Thorns ¶ £528 
Criminal damage to a dwelling Brand & Price § £1,166 
Criminal damage to a building other than a 
dwelling 
Brand & Price § £1,166 
Criminal damage to a vehicle Brand & Price § £1,166 
Serious violent offences Brand & Price § £14,009 
Less serious wounding Brand & Price § £10,845 
Common assault Brand & Price § £1,938 
Harassment  Brand & Price § £1,938 
Possession of weapons Zero rated £0 
Possession of drugs Zero rated £0 
Trafficking in controlled drugs Zero rated £0 
Credit and credit card fraud Brand & Price § £1,136 
Going equipped for stealing Zero rated £0 
Soliciting and prostitution Zero rated £0 
Breach of peace/drunk and disorderly Brand & Price § £1,938 
Begging Zero rated £0 
Domestic abuse Brand & Price § £1,938 
Kidnapped and beaten Brand & Price § £1,938 
Indecent assault Brand & Price § £42,320 
Indecent exposure Brand & Price § £1,938 
§ Brand S, Price R. The Economic and Social Costs of Crime. 2000. London: The Home 
Office.  
 
¶ Dubourg R, Hamed J, Thorns J. The economic and social costs of crime against  
individuals and households 2003/04. 2005. London: The Home Office Online Report. 
 











Table S4: Service use (unit) over follow-up by group (complete case) 
 
 PSI (n=95) TAU (n=104) 
 Mean (SD) % using Mean (SD) % using 
PSI (sessions) 4.9 (4.9) 65.2 0.0 (0.0) 0.0 
Keyworker (sessions) 8.8 (5.4) 98.3 7.4 (5.1) 97.3 
Supported accommodation (weeks) 17.6 (41.3) 20.2 22.5 (44.7) 22.1 
Inpatient (nights) 10.6 (11.3) 10.5 2.8 (1.2) 6.7 
Outpatient appointments (number) 4.4 (5.5) 15.8 4.3 (7.9) 15.4 
Accident and emergency (visits) 0.1 (0.3) 12.8 0.1 (0.3) 9.6 
Ambulance (calls) 0.8 (0.5) 9.8 0.3 (0.5) 2.3 
GP (contacts) 1.6 (2.7) 53.8 1.9 (3.0) 57.3 
Other health and social care (contact)  17.1 (51.6) 57.9 11.5 (30.9) 55.8 
Methadone (dose) 58.8 (25.0) 59.3 59.9 (25.7) 62.2 
Buprenorphine (dose) 11.4 (4.6) 28.9 11.1 (5.4) 23.7 
Criminal activity (offences) 60.0 (102.0) 22.1 59.1 (59.0) 18.3 
 Days off work over follow-up 3.3 (8.8) 26.3 1.4 (3.4) 26.3 
 
SD = standard deviation; 
PSI = personalised psychosocial intervention; 

























Table S5: Disaggregated imputed mean costs over follow-up 
 
 PSI (n=135)  TAU (n=135) Mean difference (SE) 95% CI ¶ p-value 
Therapist sessions  491 (510) - - - 
CM costs 33 (49) - - - 
Keyworker sessions 312 (234) 255 (239) -12 (26) -63 to 39 0.646 
Methadone 93 (120) 85 (115) 11 (11) -10 to 33 0.313 
Buprenorphine  31 (64) 20 (44) -9 (5) -20 to 2 0.090 
OAT dispensing 195 (128) 161 (117) -1 (9) -18 to 16 0.905 
Intervention total 1,155 (53) 521 (35) 561 (60) 443 to 680 <0.001 
Accommodation 2,048 (490) 2,888 (565) -283 (737) -1,740 to 1,173 0.701 
Hospital services 503 (199) 147 (47) 351 (191) -27 to 729 0.069 
Community health & 
social care services 
661 (168) 534 (161) 30 (234) -433 to 494 0.898 
Total NHS/PSS costs 4,367 (586) 4,090 (665) 658 (876) -1,070 to 2,388 0.453 
Absenteeism 499 (196) 132 (46) 359 (191) -32 to 751 0.070 
Victim of crime 448 (201) 592 (252) -136 (343) -818 to 545 0.691 
Criminal activity 2,507 (1,344) 4,014 (2,362) -1,843 (3,109) -8,127 to -4,442 0.557 
Total societal costs 7,822 (1,648) 8,828 (13,524) -400 (3,416) -7,274 to 6,475 0.907 
 
Data are mean (standard error, SE) in GB pounds.  
PSI = personalised psychosocial intervention; 
CM = contingency management (shop vouchers); 
OAT = opioid agonist treatment; 
TAU = treatment-as-usual; 
Mean difference, 95% CI and p-values adjusted for baseline covariates and duration of follow-













Baseline EQ-5D-3L score 0.674 (0.296) 0.649 (0.280) 0.025 
Follow-up EQ-5D-3L score 0.660 (0.335) 0.569 (0.346) 0.091 
QALYs 0.298 (0.175) 0.216 (0.109) 0.082 
 
  PSI = personalised psychosocial intervention; 




























Figure S1:  Cost-effectiveness acceptability curve showing the probability that PSI is 
cost-effective compared to TAU for different values of willingness-to-pay for a one 
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Figure S2: Scatterplot showing bootstrapped mean difference in 




TAU = treatment as usual; PSI= personalised psychosocial intervention. 
 NE = Northeast.  
 NW = Northwest.  
 SE = Southeast. 













Figure S1 Scatterplot showing the bootstrapped mean differences in imputed total costs and QALYs of PSI 
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Figure S3: Cost-effectiveness acceptability curve showing the probability that PSI is 
cost-effective compared to TAU from the NHS/PSS perspective for different values of 
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Figure S4: Cost-effectiveness acceptability curve showing the probability that PSI is 
cost-effective compared to TAU for different values of willingness-to-pay for a unit 
improvement in QALYs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
